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Therapy for chronic myeloid leukemia (CML) withtyrosine kinase inhibitors (TKIs) has made this apotentially curable disease.1,2 However, many chal-
lenges remain, including: i) defining the best TKI, dose
and schedule; ii) how to reduce the frequency and sever-
ity of adverse events (AEs); iii) how to increase the num-
ber of subjects who can achieve therapy-free remission
(TFR), and others. In this issue of Haematologica, using
data from the German CML-Study IV,2 Michel et al.3 tack-
le two of these challenges: the best TKI dose and reducing
AEs. They report that subjects randomized to receive
high-dose imatinib, 800 mg/day (d), achieving a stable
major molecular response (MMR, 0.1% of BCRABL1IS)
can have their imatinib dose reduced to 400 mg/d with-
out losing their response, with the additional benefits of
reducing AEs and cost, and likely increasing compliance.
Several prior clinical trials tested whether high-dose
imatinib, 800 mg/d, was more effective than the
approved dose, 400 mg/d.4-6 The primary end point of
most of these trials was the proportion of study subjects
achieving a MMR at 1 year, a landmark associated with a
very low risk of leukemia progression and death from
CML-related causes.7 A secondary end point was the time
to MMR achievement. The conclusion of most studies
was that high-dose imatinib resulted in faster MMRs but
later led to a similar proportion of MMRs after 1 or 2
years.4-6 However, high-dose imatinib was associated
with increased rates of ≥ grade 3 AEs, worse compliance,
and higher costs.4-6 Consequently, many study subjects
assigned to high-dose imatinib reverted to 400 mg/d.
Recently, a landmark analysis of data from the CML-
Study IV reported that study subjects receiving an opti-
mized high-dose of imatinib (median dose, 600 mg/d)
achieved deeper and faster molecular responses (MMR,
MR4 and MR4.5) compared with those receiving 400
mg/d, with no increase in ≥ grade-3 AEs.8 Importantly, the
conventional and optimized strategies of giving imatinib
resulted in similar event-free survival (EFS), progression-
free survival (PFS), and overall survival (OS).2
There are several caveats to accepting these conclusions
including biases associated with landmark analyses and
discordances between molecular responses (surrogate end
points) and clinically important end points such as EFS,
PFS and OS.9,10 Such discordances are common to many, if
not most, clinical trials and underscore the limitations of
surrogate end points.11 This is not surprising in chronic
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FIgure 1. Possible future therapeutic strategy for CML. TKI: tyrosine kinase inhibitors; MMR: major molecular response; MR: molecular response.
phase CML where more than half of the deaths are not
related to CML.2 However, the bottom line at a time of
generic imatinib is that a starting dose of 800 or 600 mg/d
reduced to 400 mg/d in subjects achieving a stable MMR
is probably a safe and effective therapeutic strategy.  
The report of Michel et al. recalls an interesting obser-
vation made several years ago in the OpTKima study.
There, some older subjects receiving imatinib 400 mg/d,
but who stopped therapy every 3rd month maintained a
MMR and sometimes even improved the depth of molec-
ular response.12 However, unlike the uniformly stable
MMRs reported by Michel et al., approximately 25% of
subjects in the OpTKima study lost their MMR. The stud-
ies differ, of course, in the fact that, in the OpTKima
study, subjects completely stopped imatinib while in the
CML-Study IV subjects had an imatinib dose reduction.
What do these data suggest?  A reasonable conclusion
is that the best strategy is to optimize initial imatinib
dose based on the rapidity, depth and stability of a sub-
ject’s molecular response rather than using the same dose
and schedule for everyone.  Alternatively, some subjects
who could benefit by starting off directly on a 2nd genera-
tion TKI,13 could be moved to lower (and less toxic)
dosages of the same drug once they achieved a good
molecular response, or eventually, in specific cases,
switch to imatinib for maintenance. Studies testing the
feasibility and the value of this approach are needed and,
indeed, some are already ongoing or planned.14
The regulatory approved dose of imatinib and other
TKIs often evolves from results of phase I safety studies
designed to determine the maximum tolerated dose
(MTD) followed by phase II and III studies of efficacy.15
This developmental scheme assumes the MTD is the
maximally effective dose (MED).  But is this assumption
correct?  In the case of CML, the MED is the dose associ-
ated with maximal inhibition of P210BCRABL1 that is also
safe, especially when given over a long period of time.
Given these considerations, it is easy to see why the
MTD and MED might differ for a TKI.15
Another issue is why different subjects respond differ-
ently to the same dose of a TKI like imatinib. Many fac-
tors could explain this heterogeneity but the most obvi-
ous is BCRABL1 mutations.16 Other variables include
pharmaco-kinetic and pharmaco-dynamic variables relat-
ed to TKI absorption and metabolism, susceptibility to
AEs, and compliance.17 Also, some subjects in chronic
phase CML have subclones with additional mutations in
genes other than BCR-ABL1 reflecting the genomic insta-
bility typical of CML.18 These subclones are not detected
by routine diagnostic procedures and may be important
in determining response to TKI-therapy and likelihood of
CML progression, obviously confounded outcomes.  In
this context, it is important to remember that there is a
substantial interval between when BCRABL1 is acquired
to when CML is diagnosed, leaving ample time for clonal
evolution.  For example, in the atom bomb survivors,
who likely acquired BCRABL1 when the atom bomb
exploded, median latency to CML diagnosis was 10 years
with a possible range of from <2 to >30 years.19
How can we best reconcile the goal of reducing the risk
and severity of AEs with the need to control or eradicate
undetected CML subclones that may require a higher TKI
dose, different TKIs, or both?  One strategy might be to
start with what might be called an ‘induction phase’ with
a high-dose of a 2nd or even a 3rd generation TKI, or high-
dose imatinib, followed by switching to a lower dose in a
‘maintenance phase’ in responders.  It might also be rea-
sonable to begin with a 2nd or 3rd generation TKI and then
switch to imatinib.
The next question is when to transition from the
‘induction’ to the ‘maintenance’ phase. The decision
could be based on surrogate end points such as MMR or
MR4, but it is also important to remember that end points
like MMR or MR4 are predictive rather than prognostic
surrogate end points.20
Which TKI is best?  Should we reduce the approved
dose of newer TKIs or switch to imatinib 400 mg/d?  This
could depend on the therapeutic goal and this may differ
in different subjects.  Is it to improve EFS, PFS or survival,
achieve TFR, decrease AEs and costs, increase compli-
ance, something else, or a combination of different goals?
When the therapeutic goal is TFR, the rapidity of achiev-
ing a deep molecular response (DMR) and its stability and
duration are crucial.21 As such, a more intensive initial
therapy strategy may be preferable.  However, this may
not be the goal in other subjects in whom survival is the
goal and where less ‘induction’ therapy may be appropri-
ate.
Another way to consider revising TKI therapeutic strat-
egy is to make treatment decisions based on time-to-
event end points with the possibility of continually revis-
ing strategy according to outcomes using statistical tech-
niques such as Markov or Bayesian adaptive models.22
This can be considered an extension of current European
LeukemiaNet recommendations,23 while also considering
additional variables, such as TKI, dose, schedule, thera-
peutic goal, AEs, pharmaco-kinetic and pharmaco-
dynamics, and others, such as the kinetics of decline of
BCRABL1 transcripts. It is even conceivable that one
might consider potency of suppression of P210BCRABL1
kinase activity in different subjects, and even activity in
CML leukemia stem cells.
The bottom line is that it is time to re-think our strategy
of using TKIs to treat CML.  We suggest testing an indi-
vidualized, precision-based approach that considers dis-
ease, patient and therapeutic goal heterogeneities, and
modifying therapy according to the rate, depth, duration
and stability of molecular response while acknowledging
poor correlations with EFS, PFS and survival.  Much work
remains to clarify these issues, and this needs to be tested
in randomized trials. 
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The human T-cell lymphotropic (or leukemia) virustype-1 (HTLV-1) was isolated by Poiesz et al. in1980 from the T-cell line Hut-102, established from
a patient thought to have cutaneous T-cell lymphoma.1
HTLV-1 causes adult T-cell leukemia/lymphoma (ATL),
HTLV-1 associated myelopathy/tropical spastic paresis
(HAM/TSP), and other inflammatory disorders.2 ATL is a
clinically heterogeneous but often very aggressive mature
T-cell neoplasm with dismal survival rates and limited
therapeutic options, particularly in the relapsed/refracto-
ry (R/R) setting.3 Most cohort studies and clinical trials in
ATL come from Japan where the virus is highly endemic
in certain regions. Here, investigators have led efforts to
define diagnostic criteria, clinical subtypes, prognostic
models, and the value of new therapies, including the
anti-CCR4 antibody mogamulizumab (KW-0761),
approved in Japan for both R/R and chemotherapy-naïve
CCR4-positive ATL.4,5 Data on subtype frequency, natural
history, and outcome in ATL from non-Japanese endemic
regions and from non-endemic regions (North America,
Europe) remain very limited, although recent studies have
begun to shed some light on this, showing that North
American ATL patients present with more aggressive dis-
ease and have a worse prognosis (median survival
approx. 7 months) compared to Japanese patients.6,7 The
availability of mogamulizumab for ATL in Japan provided
the impetus to explore its activity in other ATL popula-
tions. In this issue of Haematologica, an important study
by Phillips et al.8 significantly advances our understand-
ing of the global therapeutic impact of mogamulizumab
in ATL, by reporting results of an international random-
ized Phase II trial (KW-0761-009) assessing the safety and
efficacy of mogamulizumab versus investigator choice of
chemotherapy in patients with R/R ATL.
HTLV-1 belongs to a group of T-lymphotropic
deltaretroviruses, which includes four types of Simian T-
lymphotropic viruses (STLV). HTLV-1 is believed to have
originated from interspecies transmission between STLV-
1-infected Old-World monkeys and humans.  HTLV-1 is
highly endemic in Southwestern Japan, the Caribbean,
Northern Iran, and in Aboriginal populations in central
Australia.9 HTLV-1 RNA is reverse-transcribed into a
